Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$3.16 +10.1%	$2.55	$1.05 ▼ $4.13	$313.41M	1.89	598,142 shs	860,980 shs
GBIO Generation Bio	$0.38 +7.2%	$0.38	$0.30 ▼ $3.65	$25.37M	2.59	400,954 shs	1.08 million shs
HRMY Harmony Biosciences	$34.29 +4.7%	$33.33	$26.47 ▼ $41.61	$1.97B	0.83	633,463 shs	511,831 shs
HRTX Heron Therapeutics	$2.23 +1.4%	$2.05	$1.04 ▼ $3.73	$340.21M	1.18	2.17 million shs	1.08 million shs
MYOV Myovant Sciences	$26.98	$26.96	$7.67 ▼ $27.06	$2.62B	2.17	1.17 million shs	2.26 million shs

Beginner's Guide To Retirement Stocks

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	+5.93%	+5.93%	-22.28%	+135.39%	-6.54%
GBIO Generation Bio	+6.94%	+10.28%	-19.06%	-5.26%	-84.98%
HRMY Harmony Biosciences	+1.58%	+2.25%	-8.01%	+12.66%	+0.65%
HRTX Heron Therapeutics	+2.33%	+1.38%	+4.76%	+17.02%	-25.93%
MYOV Myovant Sciences	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADCT ADC Therapeutics	1.5247 of 5 stars	3.5	2.0	0.0	0.0	0.0	0.8	0.6
GBIO Generation Bio	3.4287 of 5 stars	3.5	3.0	0.0	0.0	1.9	3.3	1.3
HRMY Harmony Biosciences	4.821 of 5 stars	4.6	1.0	0.0	0.0	3.3	3.3	4.4
HRTX Heron Therapeutics	3.8416 of 5 stars	3.5	0.0	0.0	4.2	2.8	1.7	0.6
MYOV Myovant Sciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	3.00	Buy	$7.75	145.25% Upside
GBIO Generation Bio	3.00	Buy	$7.33	1,837.98% Upside
HRMY Harmony Biosciences	3.13	Buy	$53.63	56.39% Upside
HRTX Heron Therapeutics	3.00	Buy	$5.00	124.22% Upside
MYOV Myovant Sciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest HRTX, MYOV, ADCT, HRMY, and GBIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Outperform ➝ Moderate Buy	$8.00 ➝ $5.00
6/13/2025	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $10.00
6/9/2025	HRTX Heron Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$6.00
6/2/2025	HRMY Harmony Biosciences	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$61.00
5/15/2025	ADCT ADC Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$8.00 ➝ $8.00
5/15/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$44.00 ➝ $48.00
5/13/2025	HRMY Harmony Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	GBIO Generation Bio	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$8.00 ➝ $8.00
5/6/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$49.00 ➝ $49.00
4/28/2025	HRMY Harmony Biosciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $48.00
4/11/2025	HRTX Heron Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$4.00 ➝ $4.00

(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$70.84M	4.42	N/A	N/A	($2.10) per share	-1.50
GBIO Generation Bio	$19.89M	1.28	N/A	N/A	$1.29 per share	0.29
HRMY Harmony Biosciences	$714.73M	2.75	$3.13 per share	10.94	$11.56 per share	2.97
HRTX Heron Therapeutics	$144.29M	2.36	N/A	N/A	($0.22) per share	-10.14
MYOV Myovant Sciences	$230.97M	11.36	N/A	N/A	($5.04) per share	-5.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$157.85M	-$1.45	N/A	N/A	N/A	-197.64%	N/A	-45.57%	8/5/2025 (Estimated)
GBIO Generation Bio	-$131.67M	-$1.08	N/A	N/A	N/A	-292.92%	-75.84%	-30.40%	8/6/2025 (Estimated)
HRMY Harmony Biosciences	$145.49M	$2.62	13.09	11.03	0.48	20.53%	24.32%	15.92%	8/5/2025 (Estimated)
HRTX Heron Therapeutics	-$13.58M	-$0.06	N/A	N/A	N/A	-5.24%	N/A	-3.43%	8/5/2025 (Estimated)
MYOV Myovant Sciences	-$205.98M	-$1.91	N/A	N/A	N/A	-48.47%	N/A	-39.36%	N/A

Latest HRTX, MYOV, ADCT, HRMY, and GBIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2025	Q2 2025	GBIO Generation Bio	-$0.28	N/A	N/A	N/A	$2.51 million	N/A
8/5/2025	Q2 2025	ADCT ADC Therapeutics	-$0.36	N/A	N/A	N/A	$17.82 million	N/A
8/5/2025	Q2 2025	HRMY Harmony Biosciences	$0.78	N/A	N/A	N/A	$204.37 million	N/A
8/5/2025	Q2 2025	HRTX Heron Therapeutics	-$0.01	N/A	N/A	N/A	$38.08 million	N/A
5/14/2025	Q1 2025	ADCT ADC Therapeutics	-$0.38	-$0.36	+$0.02	-$0.36	$17.71 million	$23.03 million
5/7/2025	Q1 2025	GBIO Generation Bio	-$0.25	-$0.22	+$0.03	-$0.22	$1.70 million	$8.72 million
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million
5/6/2025	Q1 2025	HRTX Heron Therapeutics	-$0.01	$0.01	+$0.02	$0.01	$37.08 million	$38.90 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
GBIO Generation Bio	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
HRTX Heron Therapeutics	N/A	N/A	N/A	N/A	N/A
MYOV Myovant Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	4.46	4.16
GBIO Generation Bio	N/A	8.43	8.43
HRMY Harmony Biosciences	0.22	3.67	3.63
HRTX Heron Therapeutics	N/A	2.40	1.76
MYOV Myovant Sciences	N/A	1.57	1.45

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
GBIO Generation Bio	95.22%
HRMY Harmony Biosciences	86.23%
HRTX Heron Therapeutics	80.01%
MYOV Myovant Sciences	30.62%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.40%
GBIO Generation Bio	21.10%
HRMY Harmony Biosciences	23.60%
HRTX Heron Therapeutics	5.86%
MYOV Myovant Sciences	1.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	310	99.18 million	93.82 million	Optionable
GBIO Generation Bio	150	67.04 million	52.89 million	Optionable
HRMY Harmony Biosciences	200	57.42 million	43.87 million	Optionable
HRTX Heron Therapeutics	300	152.56 million	143.62 million	Optionable
MYOV Myovant Sciences	407	97.24 million	95.39 million	Not Optionable

HRTX, MYOV, ADCT, HRMY, and GBIO Headlines

Recent News About These Companies

Myovant Sciences Stock Price History

June 2, 2025 | investing.com

Myovant Investor Claiming Skadden Conflict Denied Appellate Redo

February 21, 2025 | news.bloomberglaw.comN

Myovant Investor Claiming Skadden Conflict Seeks Appellate Redo

February 14, 2025 | news.bloomberglaw.comN

Myovant Investor Fails to Revive Skadden Conflict Suit on Appeal

January 31, 2025 | news.bloomberglaw.comN

Skadden-Myovant Appeals Court Skeptical of 'Family' Conflict

January 14, 2025 | news.bloomberglaw.comN

gears of horus max win

December 28, 2024 | bweducation.businessworld.inB

Vivek Ramaswamy Net Worth 2024: How He Built a Billion-Dollar Empire

November 13, 2024 | blackstarnews.comB

Vivek Ramaswamy's Net Worth: How Donald Trump's Key Aide Made His Billions

November 13, 2024 | msn.com

Born To Indian Immigrants, Now Part Of Trump's 'DOGE' Plan – How Vivek Ramaswamy Became A Billionaire By Shedding Unprofitable Pharma Assets

November 13, 2024 | msn.com

18-year-old Vivek Ramaswamy's powerful commencement address goes viral | WATCH

November 13, 2024 | english.mathrubhumi.comE

Vivek Ramaswamy’s Net Worth: A Young Billionaire Championing Capitalism and Efficiency

November 13, 2024 | newsx.comN

Who Is Vivek Ramaswamy? Biotech Entrepreneur Appointed In Trump 2.0 Alongside Elon Musk

November 13, 2024 | newsx.comN

Global Hormone-Sensitive Advanced Prostate Cancer Treatment Market Expected to Reach USD 24.94 Billion by 2033 with a 7.2% CAGR

October 30, 2024 | fmiblog.comF

Global Prostate Cancer Diagnostics Market to Observe Stunning Growth at a CAGR of ~12% by 2030 | DelveInsight

September 25, 2024 | finance.yahoo.com

Elinzanetant Shows Significant Improvement in Menopausal Vasomotor and Sleep Symptoms

September 20, 2024 | medscape.comM

Long-Term Data Support Non-Hormonal Drug for Hot-Flash Management

September 15, 2024 | medpagetoday.comM

Forendo joins race to develop endometriosis drugs

September 12, 2024 | pharmaphorum.comP

The Scientific Establishment Is Turning 'Science' Into a Dogmatic Tool of Oppression | Opinion

September 11, 2024 | newsweek.comN

Probability in the Engineering and Informational Sciences

September 10, 2024 | cambridge.orgC

FDA clears Myovant's relugolix for uterine fibroids, setting up AbbVie clash

August 29, 2024 | pharmaphorum.comP

New MarketBeat Followers Over Time

Media Sentiment Over Time

HRTX, MYOV, ADCT, HRMY, and GBIO Company Descriptions

ADC Therapeutics NYSE:ADCT

$3.16 +0.29 (+10.10%)

Closing price 03:57 PM Eastern

Extended Trading

$3.12 -0.04 (-1.27%)

As of 06:11 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Generation Bio NASDAQ:GBIO

$0.38 +0.03 (+7.23%)

Closing price 04:00 PM Eastern

Extended Trading

$0.36 -0.01 (-3.54%)

As of 05:45 PM Eastern

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

Harmony Biosciences NASDAQ:HRMY

$34.29 +1.54 (+4.70%)

Closing price 04:00 PM Eastern

Extended Trading

$33.36 -0.93 (-2.72%)

As of 04:40 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Heron Therapeutics NASDAQ:HRTX

$2.23 +0.03 (+1.36%)

Closing price 04:00 PM Eastern

Extended Trading

$2.22 0.00 (-0.22%)

As of 06:00 PM Eastern

Heron Therapeutics, Inc., a commercial-stage biotechnology company, focuses on enhancing the lives of patients by developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Myovant Sciences NYSE:MYOV

Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time